首页> 美国卫生研究院文献>BMC Pharmacology Toxicology >In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate
【2h】

In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate

机译:婴儿利什曼原虫菌株对五价锑的体外敏感性在体外或体内传代过程中没有改变但是在接受葡甲胺的葡甲胺治疗后有所改变。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundLeishmaniasis is a common parasitic disease in Southern Europe, caused by Leishmania infantum. The failures of current treatment with pentavalent antimonials are partially attributable to the emergence of antimony-resistant Leishmania strains. This study analyses the in vitro susceptibility to pentavalent antimony of intracellular amastigotes from a range of L. infantum strains, derived from the same infected animal, during in vitro and in vivo passages and after host treatment with meglumine antimoniate.
机译:背景:利什曼病是由婴儿利什曼原虫引起的在南欧常见的寄生虫病。目前用五价锑治疗的失败部分归因于抗锑利什曼原虫菌株的出现。这项研究分析了在体外和体内传代以及用葡甲胺锑酸盐进行宿主治疗后,来自同一感染动物的一系列婴儿乳杆菌的胞内羊膜对五价锑的体外敏感性。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号